ClinicalTrials.gg
Active, not recruitingNCT05844150Updated Mar 12, 2025

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

A Phase 2 interventional study of PM8002 and Platinum in SCLC, sponsored by Biotheus Inc.. Active, not recruiting at 17 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Biotheus Inc. (part of BioNTech SE) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study to evaluate the efficacy and safety of PM8002 in combination with etoposide and platinum in first-line treatment of extensive-stage small cell lung cancer

Read the detailed description

The study is divided into two parts.

The first part is single-arm study, 50 participants were enrolled as of 21 Nov 2023,and recruitment was completed.

The second part is randomized, double-blind study, active controlled design , which will be integrated to another global III study (NCT06712355).

02

Conditions studied

  • SCLC

Keywords

  • ES-SCLC
03

In context

Lead sponsor

Biotheus Inc. is the lead sponsor of 18 studies on the registry; 8 are open to participants now.

First submitted before Biotheus Inc. became part of BioNTech SE.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed form before any trial-related processes;
  2. Age ≥18 years;
  3. or cytologically confirmed ES-SCLC;
  4. No prior systemic therapy for ES-SCLC;
  5. Have adequate organ function;
  6. The Eastern Cancer Cooperative Group () performance score of 0 or 1;
  7. of ≥12 weeks;
  8. Had at least one measurable tumor lesion according to v1.1.

Exclusion criteria

Exclusion Criteria:

  1. or cytologically confirmed mixed SCLC;
  2. History of severe allergic disease, severe drug allergy or have known allergy to any component of the study drugs;
  3. The toxicity of previous anti-tumor therapy has not been alleviated;
  4. Have received anti- therapy within 10 days prior to the first dose of the study drugs;
  5. Evidence and history of severe bleeding tendency;
  6. History of severe cardiovascular diseases within 6 months;
  7. Current presence of uncontrolled pleural, pericardial, and peritoneal effusions;
  8. History of hematopoietic stem cell transplantation or allogeneic organ transplantation;
  9. History of alcohol abuse, psychotropic substance abuse or drug abuse;
  10. (HIV) infection or known acquired immunodeficiency syndrome;
  11. Pregnant or lactating women;
  12. Other conditions considered unsuitable for this study by the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    PM8002+Etoposide+platinum

    Subjects will be administered with PM8002 plus Etoposide and platinum via intravenously (IV) Q3W for 4 cycles, followed by PM8002 until progression or for a maximum of 2 years.

    Drug: PM8002 · Drug: Platinum · Drug: Etoposide

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    ORR is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Overall survival (OS)

    OS is the time from the date of randomization or first dosing date to death due to any cause.

    Time frame: Up to approximately 2 years

  2. Progression free survival (PFS)

    Progression free survival (PFS) is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST v1.1).

    Time frame: Up to approximately 2 years

  3. Disease control rate (DCR)

    DCR is defined as the proportion of subjects with CR, PR, or stable disease (SD) based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  4. Duration of response (DOR)

    DOR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST v1.1) or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years

  5. Time to response (TTR)

    TTR is defined as the time from the start of the treatment to the first objective tumor response observed for patients who achieve CR or PR (based on RECIST v1.1).

    Time frame: Up to approximately 2 years

  6. Pharmacokinetic (PK) parameters

    The PK parameters including serum concentrations of PM8002 at different time points after study drug administration.

    Time frame: Up to 30 days after last treatment

  7. Anti-drug antibody (ADA)

    To evaluate the incidence of ADA to PM8002.

    Time frame: Up to 30 days after last treatment

  8. Treatment related adverse events (TRAEs)

    The incidence and severity of TRAEs graded according to NCI-CTCAE v5.0

    Time frame: Up to 30 days after last treatment

07

Study locations

17 sites
08

References and documents

Individual participant data

Plan to share: Yes — The data will be published or presented for publications (poster, abstract,articles or papers) or any presentations

Time frame: After the trial completed

Access criteria: NCI is committed to sharing data in accordance with NIH policy.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in May 2024, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2023
First posted
May 6, 2023
StartActual
Jun 1, 2023
Primary completionActual
May 10, 2024
CompletionEst.
Dec 2025
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05844150
Lead sponsor
Biotheus Inc.
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Jun 1, 2023
Primary completion
May 10, 2024
Completion
Dec 2025 (estimated)
Last update
Mar 12, 2025

Study contacts

Ying Cheng
principal investigator · Jilin Provincial Tumor Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pumitamig

Start the discussion